Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Harvard Business School
Merck
McKesson
Colorcon

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Details for Patent: RE39593


Email this page to a colleague

« Back to Dashboard

Summary for Patent: RE39593
Title:1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Abstract:1-phenyl-3-dimethylaminopropane compounds corresponding to the formula I ##STR00001## a method of preparing them, and the use of these substances as analgesic active ingredients in pharmaceutical compositions.
Inventor(s): Buschmann; Helmut (Esplugues de Llobregat, ES), Strassburger; Wolfgang (Wuerselen, DE), Friderichs; Elmar (Stolberg, DE)
Assignee: Gruenenthal GmbH (Aachen, DE)
Application Number:10/462,844
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE39593
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent RE39593

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Collegium Pharm Inc NUCYNTA tapentadol hydrochloride SOLUTION;ORAL 203794-001 Oct 15, 2012 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN ⤷  Free Forever Trial
Collegium Pharm Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-001 Aug 25, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY ⤷  Free Forever Trial
Collegium Pharm Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-001 Aug 25, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y RELIEF OF MODERATE TO SEVERE CHRONIC PAIN ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE39593

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany44 26 245Jul 23, 1994

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Boehringer Ingelheim
McKinsey
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.